DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Casodex (Bicalutamide) - Published Studies

 
 



Casodex Related Published Studies

Well-designed clinical trials related to Casodex (Bicalutamide)

Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects. [2010.12]

An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. [2010.02]

Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. [2009.12]

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. [2009.08.01]

Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies. [2009.04]

Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies. [2009.04]

Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer. [2007.10]

Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. [2007]

Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. [2007]

Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. [2006.09]

Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. [2006.07]

The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. [2006.07]

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. [2006.02]

Pharmacokinetics of two novel bicalutamide formulations in healthy male volunteers. [2006]

Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. [2005.12]

Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. [2005.10]

Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. [2005.07]

Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. [2005.05]

Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. [2005.02.01]

Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. [2005]

Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. [2005]

Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study. [2005]

Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. [2005]

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. [2004.11]

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. [2004.11]

Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. [2004.10.01]

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. [2004.07.01]

Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. [2004.06]

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. [2004.05]

Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. [2004.01]

Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. [2003.11]

[Effect of bicalutamide 150 mg, after 3 years of median follow-up, in non-metastatic prostatic cancer] [2003.06]

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. [2002.11]

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. [2002.09]

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. [2002.08]

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. [2001.08]

The bicalutamide Early Prostate Cancer Program. Demography. [2001.03]

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. [1999.09.01]

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. [1999.07]

Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. [1998.03]

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. [1998]

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. [1997.09]

The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. [1997.08]

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. [1996.11.15]

Randomised study of Casodex 50 MG monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. [1996.04]

[Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer] [1996.02]

Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. [1996.01]

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. [1996.01]

High-dose bicalutamide monotherapy for the treatment of prostate cancer. [1996.01]

A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. [1996.01]

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. [1996]

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. [1995.12]

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. [1995.05]

Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia. [1995.03]

A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. [1995]

Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. [1995]

Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. [1994.10]

Testicular histology after treatment with the new antiandrogen Casodex for carcinoma of the prostate. A preliminary report. [1994.03]

Current clinical studies with a new nonsteroidal antiandrogen, Casodex. [1994]

Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators. [1994]

French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report. [1994]

Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators. [1994]

Safety, side effects and patient acceptance of the antiandrogen Casodex in the treatment of benign prostatic hyperplasia. [1994]

A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia. [1993.07]

Well-designed clinical trials possibly related to Casodex (Bicalutamide)

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. [2011.05.20]

Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. [2011.05.01]

Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. [2011.02.15]

A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. [2010.09.01]

Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain? [2010.08]

A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. [2010.02]

A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. [2009.07.15]

Duration of androgen suppression in the treatment of prostate cancer. [2009.06.11]

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. [2009.05.20]

Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer. [2009.03]

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). [2008.06]

Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy. [2008.05]

Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. [2008.03.20]

Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. [2005.05]

Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. [2005.01]

Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. [2004.03]

Emerging role of adjuvant hormonal therapy. [2002.09]

Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. [2002.07]

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. [2002.04]

Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? [2000.03]

Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group. [1999.09]

Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study. [1999]

Comparison of goserelin and leuprolide in combined androgen blockade therapy. [1998.07]

Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer. [1996.11]

Other research related to Casodex (Bicalutamide)

A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. [2011.07.23]

Preliminary study with bicalutamide in heterosexual and homosexual patients with prostate cancer: a possible implication of androgens in male homosexual arousal. [2011.07]

Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer. [2011.06]

Hydroxyflutamide enhances cellular sensitivity to 5-fluorouracil by suppressing thymidylate synthase expression in bicalutamide-resistant human prostate cancer cells. [2011.03]

Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. [2010.11]

Bicalutamide plus anastrozole for the treatment of gonadotropin-independent precocious puberty in boys with testotoxicosis: a phase II, open-label pilot study (BATT). [2010.10]

Bicalutamide and third-generation aromatase inhibitors in testotoxicosis. [2010.09]

5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. [2010.08]

Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. [2010.05.15]

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. [2010.04]

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. [2010]

An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients. [2010]

Treatment of familial male-limited precocious puberty (testotoxicosis) with anastrozole and bicalutamide in a boy with a novel mutation in the luteinizing hormone receptor. [2009.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017